IBC Review Procedures
Institutional Biosafety Committee receives the Initial rDNA Research Classification form or Infectious Agent/Toxin Questionnaire (IAQ) with a copy of
the Proposed Project Questionnaire for new project or grant renewal.
rDNA: If not exempt, IBC analyst requests investigator to complete the Recombinant DNA Research Questionnaire for new project.
Exempt determination
made by the IBC
Associate Director (or
designee)
Associate Director (or
designee) signs
exempt letter
Biosafety officer (BSO)
and IBC chair receive
copy
Reported to the committee
at next meeting
Risk Group 1 in vitro
and in vivo [including
transgenic animal
projects]
Review by Associate
Director (or designee)
Included in Committee epackets. Committee votes at
next scheduled
videoconference or convened
meeting
Approval signed by Associate
Director or designee
(Biosafety officer and Chair
receive copy)
All Others
Reviewed by IBC
Committee at convened* or
videoconference meeting
Approval signed by IBC chair or
designee (Biosafety officer
receives copy)
*New projects covered by Section III-A-III-C of the
NIH Guidelines (experiments requiring NIH Director,
OBA, and/or RAC review) and new Select Agent work
will be reviewed at a convened meeting
For non-recombinant infectious or select agents:
1. IBC will review all research using Select Agents (except exempt quantities of toxins) or Risk Group III agents (in vivo and in vitro)
2. For Risk Group II agents (in vitro or in vivo), BSO will review, with input from IBC Chair/ Associate Director/Committee as needed. Reported to the
committee at the next meeting.
rev. 4/05/10